Core Viewpoint - Baipusais has officially submitted its prospectus to the Hong Kong Stock Exchange, projecting a significant revenue growth of approximately 30% to around 837 million yuan for the fiscal year 2025 compared to 2024 [1]. Group 1: Financial Performance - The company reported a revenue of 613 million yuan for the first three quarters of 2025, reflecting a year-on-year increase of 32.26% [5]. - As of September 30, 2025, Baipusais held over 1.53 billion yuan in cash, but its return on equity (ROE) has declined to 5.06% [2][8]. - The company’s net profit for 2024 was 120 million yuan, while the net cash flow from operating activities was only 85 million yuan, indicating a gap of over 30 million yuan [8]. Group 2: Inventory and Operational Risks - Baipusais has seen its inventory value rise from 137 million yuan at the end of 2023 to 256 million yuan by September 2025, an increase of 86.86% [10]. - The proportion of inventory to current assets has doubled from 6.20% to approximately 14.00% during the same period, raising concerns about potential price depreciation [10]. - The company has begun to recognize significant impairment losses, with a total of 32.81 million yuan in impairment losses for the third quarter of 2025, primarily due to inventory write-downs [10]. Group 3: Strategic Initiatives - Baipusais aims to establish a global supply chain network to mitigate the complexities of the geopolitical environment, with a focus on expanding its high-standard GMP production facilities and AI platforms [2][5]. - The company has achieved a 100% repurchase rate from its top 20 clients, indicating strong customer retention [5]. - The management believes that the IPO will help attract more long-term international capital to optimize the shareholder structure [5]. Group 4: Market Position - Baipusais is ranked first among domestic recombinant protein suppliers in China and third globally, according to Frost & Sullivan data [6]. - The company has developed over 5,000 specifications of recombinant proteins and antibodies, penetrating deeply into the top 20 global pharmaceutical companies [5][6]. - The governance structure shows a high concentration of ownership, with the founder and related parties holding approximately 41.48% of the shares [6].